Analysts expect Forte Biosciences, Inc. to report revenue of 0.00 for Q2 26, against a range of 0.00 to 0.00. The most recent reported quarter, Q1 26, came in at 0.00.
| Metric | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - |
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analysts expect Forte Biosciences, Inc. to report earnings per share of -0.83 for Q2 26, against a range of -0.88 to -0.78. The most recent reported quarter, Q1 26, came in at -1.24, a 3.3% miss against the -1.20 consensus.
| Metric | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -6.75 | -4.54 | 3.12 | -1.37 | -0.96 | -0.99 | -1.39 | -1.24 | - | - | - | - | - | - | - | - | |||||||||||
| High Estimate | -3.78 | -5.69 | -1.92 | -0.90 | -1.01 | -0.98 | -1.19 | -1.08 | -0.78 | -0.90 | -0.86 | -0.79 | -0.14 | 0.03 | -0.07 | -2.05 | |||||||||||
| Low Estimate | -4.56 | -6.19 | -2.22 | -1.08 | -1.11 | -1.08 | -1.31 | -1.32 | -0.88 | -1.02 | -1.02 | -0.91 | -0.16 | 0.03 | -0.07 | -2.21 | |||||||||||
| Consensus Estimate | -4.17 | -5.94 | -2.07 | -0.99 | -1.06 | -1.03 | -1.25 | -1.20 | -0.83 | -0.96 | -0.94 | -0.85 | -0.15 | 0.03 | -0.07 | -2.13 |